Adagene Inc.
NASDAQ:ADAGBiotechnology
+$0.13 today
- Market cap
- $75.67M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
Volume 1.18M
Average 0.21M
Returns on capital
Adagene Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.8%
avg -25.2%
ROIC
-36.2%
avg -39.4%
ROA
-22.5%
avg -28.8%
Analysis
ROA is currently the strongest return metric at -22.5% versus its period average of -28.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Guizhong Liu | Senior Vice President of Early Drug Discovery | — | 55 | — | — |
Jiping Zha | Executive Vice President of Clinical Development | — | — | — | — |
Yan Li | Senior Vice President of Bioinformatics & Information Technology | — | 51 | — | — |
Mickael Chane-Du | Chief Strategy Officer | — | — | — | — |
Qinghai Zhao | Chief Manufacturing Officer | — | 65 | 1.25K | <0.01% |
Chunfang Gu | Executive Director of Finance | — | — | 0 | <0.01% |
Alexander Goergen | Vice President & Head of Business Development | — | 39 | — | — |
Ling Zhou | Executive Director & Head of Human Resources | — | — | 1.25K | <0.01% |
Xiaohong She | Senior Vice President & Head of Clinical Operations | — | 59 | — | — |
Man Kin Tam | Chief Financial Officer & Director | — | 49 | 12.00K | 0.03% |
Peter Luo | Co- Founder, Chairman, Chief Executive Officer and President of R&D | — | 60 | 88.53K | 0.24% |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$162,244.33
Sells
0
$0.00
Net Transaction Value
+$162,244.33
Net buying
Most Active
Luo Peter
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 23, 26Sep 23, 2026 | Tam Man Kin Direct | Buy | $6K$6,000.00 |
| Sep 16, 26Sep 16, 2026 | Luo Peter Direct | Buy | $64K$63,980.46 |
| Aug 14, 26Aug 14, 2026 | DO CUONG V Direct | Buy | $7.5K$7,500.00 |
| Aug 5, 26Aug 5, 2026 | Luo Peter Direct | Buy | $1K$1,018.35 |
| Aug 4, 26Aug 4, 2026 | Luo Peter Direct | Buy | $83.7K$83,745.52 |
Summary
Insiders reported 5 buys worth $162,244.33 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $162,244.33. Luo Peter was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -6.2% | +4.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -6.2% over three years. Forward estimates point to Revenue at +4.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Adagene Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ADAG's management, answered from reported figures.
Who manages ADAG?
Adagene Inc. (ADAG) lists 11 active executives. The top listed executive is Guizhong Liu, Senior Vice President of Early Drug Discovery.
Are ADAG insiders buying or selling?
Recent insider activity shows net buying of $402,244.33.
Continue the stock analysis
Jump to another research area for this company.